Lecanemab

Eisai and BioArctic’s Leqembi Iqlik, a subcutaneous formulation of lecanemab for Alzheimer’s, has been named one of TIME’s ‘Best Inventions of 2025’. This recognition highlights its potential in targeting amyloid-beta. Leqembi, developed through collaboration and based on BioArctic’s research, is approved in multiple countries for early Alzheimer’s. The subcutaneous option offers a more convenient administration route. Analysts predict this award may boost investor confidence in BioArctic and Eisai. BioArctic retains Nordic commercialization rights and receives milestone payments and royalties.

Eisai, in partnership with BioArctic AB, is launching Leqembi in Europe, starting with Austria and Germany. Leqembi, approved by the European Commission in April 2025, is the first therapy targeting the underlying cause of Alzheimer’s disease (AD). Indicated for early AD patients (ApoE ε4 non-carriers or heterozygotes) with confirmed amyloid pathology, Leqembi demonstrated a 31% reduction in clinical decline in trials. Lecanemab selectively binds to aggregated soluble and insoluble forms of amyloid-beta (Aβ). It has already been approved in U.S., Japan, EU, China, etc. Common adverse reactions include infusion-related reactions and ARIA.